Have a personal or library account? Click to login
No evidence of the long-term in vitro toxicity of Aeroxide P25 TiO2 nanoparticles in three mammalian cell lines despite the initial reduction of cellular mitochondrial activity Cover

No evidence of the long-term in vitro toxicity of Aeroxide P25 TiO2 nanoparticles in three mammalian cell lines despite the initial reduction of cellular mitochondrial activity

Open Access
|Feb 2024

Figures & Tables

Fig. 1.

SSB and base damage recognized by FPG in A549, HepG2 or HT29 cells treated with Aeroxide P25 TiO2 NP for 2 h (left panel) and 24 h (right panel) at concentrations indicated. Numbers (1, 2) denote results of Tukey’s test post hoc analysis, indicating a significant difference of the means from the control when NP concentration was considered (1) or a significant difference of the means between the same NP concentration, but different treatment times (2).
SSB and base damage recognized by FPG in A549, HepG2 or HT29 cells treated with Aeroxide P25 TiO2 NP for 2 h (left panel) and 24 h (right panel) at concentrations indicated. Numbers (1, 2) denote results of Tukey’s test post hoc analysis, indicating a significant difference of the means from the control when NP concentration was considered (1) or a significant difference of the means between the same NP concentration, but different treatment times (2).

Fig. 2.

Mitochondrial activity (MTT assay) of cells treated with Aeroxide P25 TiO2 NP for 24 h and measured 72 h after treatment expressed as a percent of the control (untreated cells). The asterisk denotes a statistically significant difference from the control. Two-way ANOVA with Tukey’s HDS post hoc comparison. P < 0.05.
Mitochondrial activity (MTT assay) of cells treated with Aeroxide P25 TiO2 NP for 24 h and measured 72 h after treatment expressed as a percent of the control (untreated cells). The asterisk denotes a statistically significant difference from the control. Two-way ANOVA with Tukey’s HDS post hoc comparison. P < 0.05.

Fig. 3.

Short-term survival of cells treated with Aeroxide P25 TiO2 NP for 24 h, as measured by neutral red assay. The asterisk denotes a statistically significant difference from the control. Two-way ANOVA with Tukey’s HDS post hoc comparison. P < 0.05.
Short-term survival of cells treated with Aeroxide P25 TiO2 NP for 24 h, as measured by neutral red assay. The asterisk denotes a statistically significant difference from the control. Two-way ANOVA with Tukey’s HDS post hoc comparison. P < 0.05.

Fig. 4.

Cloning ability determination of A549, HT29 and HepG2 cells growing in the presence of Aeroxide P25 TiO2 NP.
Cloning ability determination of A549, HT29 and HepG2 cells growing in the presence of Aeroxide P25 TiO2 NP.

Fig. 5.

Generation of ROS in HepG2, A549 and HT29 cells incubated with Aeroxide P25 TiO2 NP. H2O2 in a concentration of 1 mM served as a positive control. The data provided are in the form mean ± SD. n denotes the number of experiments; n = 3. The asterisk denotes statistically significant difference from unexposed control, P < 0.05.
Generation of ROS in HepG2, A549 and HT29 cells incubated with Aeroxide P25 TiO2 NP. H2O2 in a concentration of 1 mM served as a positive control. The data provided are in the form mean ± SD. n denotes the number of experiments; n = 3. The asterisk denotes statistically significant difference from unexposed control, P < 0.05.

Frequency of micronuclei and mean number of γ-H2AX foci per nucleus after 2 h and 24 h treatment with TiO2 NP concentrations indicated, and with the effect of X-irradiation with 2 Gy shown for comparison

Micronuclei frequency
TreatmentDoseCell line/time of treatment
A549HepG2HT29
2 h24 h2 h24 h2 h24 h
Control 22.9 ± 9.531.5 ± 2.034.6 ± 3.426.3 ± 7.85.9 ± 3.27.5 ± 1.8
X-ray2 Gy80.1 ± 5.2a155.2 ± 7.7a45.5 ±0.3a
TiO2 NP 21 nm10 μg/mL33.2 ± 6.926.8 ± 7.522.3 ± 8.827.0 ± 9.56.8 ± 1.08.5 ± 6.6
50 μg/mL22.5 ± 9.625.2 ± 3.724.6 ± 4.523.0 ± 4.45.5 ± 0.97.8 ± 1.6
100 μg/mL25.5 ± 5.830.0 ± 8.224.5 ± 12.523.5 ± 6.46.1 ± 2.810.0 ± 7.2
The mean number of γ-H2AX foci per nucleus
TreatmentDoseCell line/time of treatment
A549HepG2HT29
2 h24 h2 h24 h2 h24 h
Control 10.8 ± 5.710.7 ± 3.023.6 ± 10.87.2 ± 2.125.5 ± 10.126.4 ± 10.1
X-ray2 Gy78.2 ± 10.2a87.2 ± 10.0”87.9 ± 3.4a
TiO2 NP 21 nm10 μg/mL11.2 ± 6.810.5 ± 3.121.1 ± 6.09.7 ± 4.025.4 ± 10.025.0 ± 9.4
50 μg/mL10.3 ± 3.57.8 ± 1.519.3 ± 5.611.4 ± 2.726.6 ± 6.823.7 ± 8.8
100 μg/mL10.6 ± 4.16.4 ± 2.518.3 ± 8.09.5 ± 3.228.0 ± 5.024.5 ± 10.5

The extent of apoptosis after 2 h and 24 h treatment with TiO2 NP at indicated concentrations

TreatmentDoseCell line/time of treatment
A549HepG2HT29
2h24 h2h24 h2h24 h
ControlViable99.16 ± 0.1498.36 ± 0.1697.63 ± 0.2996.34 ± 0.4398.03 ± 0.5597.04 ± 0.69
Early apoptosis0.54 ± 0.211.34 ± 0.262.20 ± 0.303.22 ± 0.291.80 ± 0.562.61 ± 0-43
Late apoptosis and necrosis0.30 ± 0.100.30 ± 0.080.17 ± 0.150.44 ± 0.170.17 ± 0.060.35 ± 0.09
Staurosporine/24 hbViable32.48 ± 8.88a23.70 ± 5.33a20.20 ± 3.20a
Early apoptosis7.98 ± 2.33a48.20 ± 3.22a58.03 ± 4.98a
Late apoptosis and necrosis59.54 ± 3.99a28.10 ± 2.56a21.77 ± 2.37a
TiO2 NP 10 mg/mLViable93.07 ± 0.81a93.30 ± 1.20a93.20 ± 0.26a92.93 ± 0.64a93.13 ± 0.25a92.50 ± 1.46a
Early apoptosis5.10 ± 0.44a4.70 ± 0.75a5.03 ± 1.034.53 ± 0.40a4.43 ± 0.754.17 ± 0.79
Late apoptosis and necrosis1.83 ± 0.40a2.00 ± 0.46a1.77 ± 0.812.53 ± 0.26a2.43 ± 0.50a3.33 ± 0.81a
TiO2 NP 50 mg/mLViable92.10 ± 0.80a93.93 ± 1.75a93.97 ± 0.65a91.13 ± 1.37a93.17 ± 0.78a91.83 ± 1.60a
Early apoptosis5.97 ± 0.76a3.83 ± 1.33a3.97 ± 0.616.00 ± 1.15a3.70 ± 0.605.17 ± 1.40a
Late apoptosis and necrosis1.93 ± 0.15a2.23 ±0.42a2.07 ±0.15a2.87 ± 0.35a3.13 ±0.25a3.00 ± 0.26a
TiO2NP 100 mg/mLViable93.63 ± 1.20a91.87 ± 1.10a93.73 ± 0.64a90.87 ± 0.96a92.23 ± 1.46a90.57 ± 0.23a
Early apoptosis3.97 ± 0.75a5.90 ± 1.47a4.27 ± 0.40a6.33 ± 0.91a4.70 ± 0.79a6.17 ± 0.65a
Late apoptosis and necrosis2.40 ± 0.46a2.23 ± 0.40a2.00 ± 0.26a2.80 ± 0.26a3.07 ± 0.81a3.27 ± 0.47a

Caspase 3 activity after 2 h and 24 h treatment with TiO2 NP at indicated concentrations

TreatmentCell line/time of treatment
A549HepG2HT29
2 h24 h2 h24 h2 h24 h
Control0.12 ±0.050.05 ±0.011.02 ±0.031.42 ±0.020.26 ±0.020.42 ±0.03
TiO2 NP 10 mg/mL0.10 ± 0.020.06 ± 0.010.98 ± 0.021.43 ± 0.090.31 ± 0.010.41 ± 0.06
TiO2 NP 50 mg/mL0.13 ± 0.020.07 ± 0.011.08 ± 0.071.37 ± 0.050.51 ± 0.05a0.63 ±0.05a
TiO2 NP 100 mg/mL0.11 ± 0.010.07 ± 0.011.39 ± 0.06a1.39 ± 0.030.37 ± 0.02a0.55 ± 0.04a
Positive control: Jurkat cells treated with 1 mM staurosporine for 24 h : 39.89 ± 3.82a

Hydrodynamic diameter and zeta potential of Aeroxide P25 TiO2 NPs in water, EMEM, F12 and DMEM media

MediumHydrodynamic diameter (nm)Polydispersity index (PDI)Zeta potential 7.4 (mV)
Water356 ± 10.457 ± 0.04–15.3 ± 0.5
EMEM246 ± 10.193 ± 0.07–25.5 ± 0.6
F12295 ± 30.220 ± 0.05–28.7 ± 2.5
DMEM300 ± 20.280 ± 0.07–27.5 ± 0.2
DOI: https://doi.org/10.2478/nuka-2024-0002 | Journal eISSN: 1508-5791 | Journal ISSN: 0029-5922
Language: English
Page range: 13 - 22
Submitted on: Mar 8, 2023
|
Accepted on: Nov 27, 2023
|
Published on: Feb 23, 2024
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2024 Sylwia Męczyńska-Wielgosz, Teresa Bartłomiejczyk, Iwona Grądzka, Sylwester Sommer, Aneta Węgierek-Ciuk, Anna Lankoff, Katarzyna Sikorska, Maria Wojewódzka, Małgorzata Dobrzyńska, Marcin Kruszewski, published by Institute of Nuclear Chemistry and Technology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.